# EDGAR Filing Document

**Accession Number:** 0001727492
**File Stem:** 0001420506-25-002664
**Filing Date:** 2025-9
**Character Count:** 9336
**Document Hash:** dee0c70fcce5ade060bd2ac758255397
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001420506-25-002664.hdr.sgml**: 20250902

**ACCESSION NUMBER**: 0001420506-25-002664

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250902

**EFFECTIVENESS DATE**: 20250902

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Caligan Partners LP
- **CENTRAL INDEX KEY:** 0001727492

**ORGANIZATION NAME:**
- **EIN:** 822603419
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-23096
- **FILM NUMBER:** 251282337

**BUSINESS ADDRESS:**
- **STREET 1:** 780 THIRD AVENUE
- **STREET 2:** 30TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** 718-570-6018

**MAIL ADDRESS:**
- **STREET 1:** 780 THIRD AVENUE
- **STREET 2:** 30TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001727492

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** Caligan Partners LP

**Address:** 780 THIRD AVENUE, NEW YORK, NY 10017

**Telephone number:** 646-859-8207

**Name of agent for service:** Tiffany Crowley

**Agent Address:** 780 THIRD AVENUE, NEW YORK, NY 10017

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-23096

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** —

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 0

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER                | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                                                                                                                    | VOTE CATEGORY                |   SHARES VOTED |   SHARES ON LOAN | HOW VOTED   |   SHARES VOTED FOR OR AGAINST MANAGEMENT | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|---:|:---|:---|
| Anika Therapeutics Inc.       | 035255108 | 07/09/2024     | Advisory vote on the compensation of the Company's named executive officers                                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |        1360450 |                0 | FOR         |                                  1360450 | FOR                         |  |
| Alimera Sciences Inc.         | 016259202 | 09/04/2024     | To approve, by non-binding, advisory vote, the compensation that will or may be paid or become payable to our named executive officers that is based on or otherwise relates to the Merger                                                          | SECTION 14A SAY-ON-PAY VOTES |       16835154 |                0 | FOR         |                                 16835154 | FOR                         |  |
| AGIOS PHARMACEUTICALS, INC.   | 00847X104 | 06/18/2025     | Advisory vote on the compensation of the Company's named executive officers                                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |         578827 |                0 | FOR         |                                   578827 | FOR                         |  |
| Anika Therapeutics Inc.       | 035255108 | 06/20/2025     | Advisory vote on the compensation of the Company's named executive officers                                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |        1434130 |                0 | AGAINST     |                                  1434130 | FOR                         |  |
| ASTELLAS PHARMA INC.          | J03393105 | 06/19/2025     | Approve details of the compensation to be received by Outside Directors                                                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |         691375 |          1879225 | FOR         |                                   691375 | FOR                         |  |
| BIOCRYST PHARMACEUTICALS,INC. | 09058V103 | 06/12/2025     | To hold a non-binding, advisory vote regarding executive compensation                                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |        2332709 |                0 | FOR         |                                  2332709 | FOR                         |  |
| Evolus                        | 30052C107 | 06/05/2025     | Approval of, on an advisory basis, the compensation of Evolus' named executive officers                                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |        2148944 |                0 | FOR         |                                  2148944 | FOR                         |  |
| Exelixis Inc                  | 30161Q104 | 05/28/2025     | To approve, on an advisory basis, the compensation of Exelixis' named executive officers, as disclosed in the accompanying Proxy Statement                                                                                                          | SECTION 14A SAY-ON-PAY VOTES |         740980 |                0 | FOR         |                                   740980 | FOR                         |  |
| LIQUIDIA CORPORATION          | 53635D202 | 06/17/2025     | To approve, on an advisory basis, the compensation of our named executive officers                                                                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |        1808047 |                0 | FOR         |                                  1808047 | FOR                         |  |
| MERUS N.V.                    | N5749R100 | 05/21/2025     | Approval, on an advisory basis, of the compansation of Merus N.V.'s named executive officers                                                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES |         270205 |                0 | FOR         |                                   270205 | FOR                         |  |
| REVOLUTION MEDICINES, INC.    | 76155X100 | 06/26/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company'snamed executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay"). | SECTION 14A SAY-ON-PAY VOTES |         360405 |                0 | FOR         |                                   360405 | FOR                         |  |
| SAGE THERAPEUTICS, INC.       | 78667J108 | 06/11/2025     | To hold a non-binding advisory vote to approve the compensation paid to ournamed executive officers.                                                                                                                                                | SECTION 14A SAY-ON-PAY VOTES |        3052558 |                0 | AGAINST     |                                  3052558 | FOR                         |  |
| VERRICA PHARMACEUTICALS INC.  | 92511W108 | 06/05/2025     | Approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the proxy statement.                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |        9188212 |                0 | FOR         |                                  9188212 | FOR                         |  |

## N-PX: Signature Block

**Reporting Person:** Caligan Partners LP

**By (Signature):** Tiffany Crowley

**By (Printed Signature):** Tiffany Crowley

**By (Title):** Chief Financial Officer/Chief Compliance Officer

**Date:** 08/29/2025